Voice Feminisation in Transgender Women (FemVoc)

• ClinicalTrials.gov Identifier: NCT03899896
• Recruitment Status: Unknown
• First Posted: April 2, 2019
• Last Update Posted: April 2, 2019
• Sponsor: Central Hospital, Nancy, France
• Information provided by (Responsible Party): Central Hospital, Nancy, France

Study Description

Brief Summary:

The voice is a reflection of our identity. In the case of transgender women, there may be a gap between perceived male voice and female appearance. Indeed, hormonal treatment in transgender women has no effect on the voice quality. This gap can have negative consequences on everyday life in banal situations such as telephonic contact leading to limited use of phone calls and social isolation.

Differences between female and male voices seem to be socially determined and do not depend directly on sexual dimorphism of the phonatory organs.

Speech therapy might thus be indicated as a vocal support for transgender women.

Only few studies have examined the impact of perceived voice on the quality of life of transgender women.

Condition or disease
Speech Therapy; Transgender Women; Gender Dysphoria

Study Design

• Study Type: Observational
• Estimated Enrollment: 144 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Voice Feminisation in Transgender Women
• Actual Study Start Date: February 28, 2019
• Estimated Primary Completion Date: February 28, 2020
• Estimated Study Completion Date: March 30, 2020

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. To measure the perceptions of transgender women regarding their voice [ Time Frame: 1 year ]
   Transsexual voice questionnaire Male-to-Female Transsexuals (Dacakis G et al J Voice, 2017): the questionnaire evaluates voice perception in 6 domains: 1 / effect of voice on ease of social interactions, 2 / effect of voice on emotions; 3 / relationship between voice and gender identity, 4 / effort and concentration required to produce voice; 5 / physical aspects of voice production; 6 / pitch. The questionnaire has 30 items. The subject indicates on a 4-point Likert scale ranging from "never or rarely" to "often enough or all the time", the frequency with which he usually feels the symptoms listed. The score is calculated from a minimum of 30 points to a maximum of 120 points

Secondary Outcome Measures :

1. generic quality of life: physical functioning, limitations due to physical state, pain, mental health, limitations due to mental state, social health, vitality and global health [ Time Frame: 1 year ]
   Questionnaire (Short form 36 health survey) The SF-36 is a generic quality of life self-questionnaire with 36 items grouped in 8 dimensions (physical functioning, limitations due to physical state, pain, mental health, limitations due to mental state, social health, vitality and global health). For each dimension a quality of life score is calculated and normalized between 0 (worst possible QoL) and 100 (best QoL possible).
2. Anxiety: State-Trait Anxiety Inventory, STAI-Y [ Time Frame: 1 year ]
   • The STAI-Y assesses anxiety as a personality trait and as a specific emotional response to a situation. The first part, STAI-Y-1, consists of 20 sentences assessing the current emotional state of the subject. The second part, STAI-Y-2, consists of 20 sentences assessing the subject's usual emotional state.
   • Each answer to an item in the STAI-Y is scored from 1 to 4, with 1 indicating the lowest degree of anxiety and 4 the highest degree of anxiety.
   • In the STAI-Y-1, the subject indicates the intensity of his feelings on a 4-point Likert scale ranging from "not at all" to "many". In the STAI-Y-2, the subject indicates on a 4-point Likert scale ranging from "almost never" to "almost always", a frequency at which he usually feels the symptoms listed.
   • To obtain the score for the STAI-Y-1, the scores for the 20 items (1 to 20) are summed. To obtain the STAI-Y-2 score, the scores for the 20 items (21 to 40) are summed. Each score can therefore vary from 20 to 80.
3. Self-esteem : Physical self inventory, 25 items (PSI-25) [ Time Frame: 1 year ]
   • The PSI-25 is an inventory of self-esteem relating to the body domain.
   • This tool consists of 6 scales: at the general level, the overall self-esteem scale, at the physical domain level:

   the perceived physical value scale, and at the subdomain level, 4 subscales: the fitness, athletic competence, physical appearance and strength. It has 25 items

   • The subject responds on the Likert scale in 6 increasing degrees (it looks like me 1: not at all, 2: very little, 3: a little, 4: enough, 5: a lot, 6: quite).
   • The score ranges from 5 to 30 for each scale, total score is averaged.
4. Depression: Center for Epidemiologic Studies Depression Scale, CES-D [ Time Frame: 1 year ]

   • The CES-D assesses the frequency and severity of depressive symptoms presented by the general population.

   The questionnaire has 20 items.

   • The subject indicates on a 4-point Likert scale ranging from "almost never" to "almost always", a frequency at which he usually feels the symptoms listed.
   • Score is calculated from 0 to 60 (maximum score indicating strong expression of symptoms)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

Participation to the study will be proposed consecutively to all subjects, fulfilling inclusion criteria, attending in-office follow-up visit for gender dysphoria in the Department of Endocrinology, Diabetology and Nutrition of the University Hospital of Nancy

Criteria

Inclusion Criteria:

• Age ≥ 18 years
• Follow-up in the Department of Endocrinology, Diabetology and Nutrition of the University Hospital of Nancy
• Gender dysphoria according to the ICD 11
• Voluntary, informed consent to participate in research
• Compulsory affiliation to the social security system

Exclusion Criteria:

-Refusal or incapacity to be involved in the study

Contacts and Locations

Contacts

Contact: Eva Feigerlova, MD, PhD; +33(0)383153412; e.feigerlova@chru-nancy.fr

Locations

France

University Hospital Nancy; Recruiting

Vandoeuvre les nancy, France, 54511

Contact: Eva Feigerlova, MD, PhD +33(0)383153412

Sponsors and Collaborators

Central Hospital, Nancy, France

More Information

• Responsible Party: Central Hospital, Nancy, France
• ClinicalTrials.gov Identifier: NCT03899896
• Other Study ID Numbers: 2019
• First Posted: April 2, 2019
• Last Update Posted: April 2, 2019
• Last Verified: March 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Communication Disorders; Feminization; Gender Dysphoria; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Neurodevelopmental Disorders; Mental Disorders; Sexual Dysfunctions, Psychological